Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics Evrópusambandið - íslenska - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - yfirborðs mótefna gegn inflúensuveiru (haemagglutinin og neuraminidasa) á stofn a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - bóluefni - virkt bólusetning gegn h5n1 undirgerð inflúensu a veiru. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Zoonotic Influenza Vaccine Seqirus Evrópusambandið - íslenska - EMA (European Medicines Agency)

zoonotic influenza vaccine seqirus

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - bóluefni - active immunisation against h5 subtype of influenza a virus.

COVID-19 Vaccine (inactivated, adjuvanted) Valneva Evrópusambandið - íslenska - EMA (European Medicines Agency)

covid-19 vaccine (inactivated, adjuvanted) valneva

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - bóluefni - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Marcain spinal tung Stungulyf, lausn 5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

marcain spinal tung stungulyf, lausn 5 mg/ml

aspen pharma trading limited - bupivacainum hýdróklóríð - stungulyf, lausn - 5 mg/ml

Pandemic Influenza Vaccine H5N1 Baxter AG Evrópusambandið - íslenska - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 baxter ag

resilience biomanufacturing ireland limited - inflúensubóluefni (heil veiru, óvirkt) sem inniheldur mótefnavaka af: a / víetnam / 1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - bóluefni - fyrirbyggjandi inflúensu í opinberlega lýst faraldur ástandið. bólusetning gegn heimsfaraldri inflúensu ætti að nota í samræmi við opinbera leiðbeiningar.

Marcain spinal Stungulyf, lausn 5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

marcain spinal stungulyf, lausn 5 mg/ml

aspen pharma trading limited - bupivacainum hýdróklóríð - stungulyf, lausn - 5 mg/ml

Marcain Stungulyf, lausn 2,5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

marcain stungulyf, lausn 2,5 mg/ml

aspen pharma trading limited - bupivacainum hýdróklóríð - stungulyf, lausn - 2,5 mg/ml

Marcain Stungulyf, lausn 5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

marcain stungulyf, lausn 5 mg/ml

aspen pharma trading limited - bupivacainum hýdróklóríð - stungulyf, lausn - 5 mg/ml

Alcaine Augndropar, lausn 5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alcaine augndropar, lausn 5 mg/ml

alcon nordic a/s - proxymetacainum hýdróklóríð - augndropar, lausn - 5 mg/ml

Marcain adrenalin Stungulyf, lausn 2,5 mg/ml+5 míkróg/m Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

marcain adrenalin stungulyf, lausn 2,5 mg/ml+5 míkróg/m

aspen pharma trading limited - bupivacainum hýdróklóríð; adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 2,5 mg/ml+5 míkróg/m